Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05124912 · ClinicalTrials.gov registry record · NA

REMASTer: REcurrent Brain Metastases After SRS Trial

A NA study of Brain Metastases and Radiation Necrosis, sponsored by Monteris Medical.

Recruiting
Registry status
NA
Development phase
261
Enrollment target
9
Study locations

NCT05124912: Recruiting NA study of Brain Metastases and Radiation Necrosis, sponsored by Monteris Medical.

NCT05124912 is a NA study of Brain Metastases and Radiation Necrosis that is actively recruiting participants, run by Monteris Medical. The registered enrollment target is 261 participants, above the 209-participant average among 67 other Brain Metastases trials with a reported enrollment target (25% higher). The trial reports 9 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05124912, a NA study of Brain Metastases and Radiation Necrosis, is actively recruiting participants, sponsored by Monteris Medical.

RECRUITING
Registry status
NA
Development phase
261 participants
Enrollment target
9
Study locations

Study Summary

Randomized, post-market multi-center study investigating the efficacy of two sets of treatment algorithms in brain metastases (BM) patients at the time of first intervention for radiographic progression after stereotactic radiosurgery (SRS), with or without surgery.

Primary Outcome

Determine the effectiveness of LITT using the NeuroBlate® System with or without repeat SRS on recurrent brain metastases, as measured by freedom from local progression.

Interventions

  • DRUG Steroid Therapy
  • PROCEDURE Radiation Therapy
  • PROCEDURE Laser Interstitial Thermal Therapy

Study Locations (9)

North Carolina

  • Duke University Hospital - Durham
  • Wake Forest Baptist Medical Center - Winston-Salem

Ohio

  • Cleveland Clinic - Cleveland
  • Kettering Health - Kettering

California

  • UCLA - Los Angeles

Illinois

  • University of Chicago - Chicago

Maryland

  • University of Maryland - Baltimore

Missouri

  • WashU - St Louis

Wisconsin

  • Medical College of Wisconsin - Milwaukee

Trial Details

FieldValue
Enrollment Target 261 participants
Start Date 2022-05-10
Est. Completion 2028-10
Phase NA
Monteris Medical

8 total trials

What NCT05124912 shows while recruiting

NCT05124912 is an interventional study that assigns participants to a tested intervention. The registered 261 participants enrollment target is mid-sized for trials with a published cap, above the 209-participant average among 67 other Brain Metastases trials with a reported enrollment target (25% higher).

The record links to 4 conditions, with Brain Metastases appearing as the primary indexed condition, and to 3 interventions - of which Steroid Therapy is the first listed.

NCT05124912 lists 9 locations in 7 states (North Carolina, Ohio, California).

Frequently Asked Questions

What is clinical trial NCT05124912 about?

NCT05124912 is a clinical study titled "REMASTer: REcurrent Brain Metastases After SRS Trial". Randomized, post-market multi-center study investigating the efficacy of two sets of treatment algorithms in brain metastases (BM) patients at the time of first intervention for radiographic progression after stereotactic radiosurgery (SRS), with or without surgery.

What is the current status of trial NCT05124912?

This trial is currently recruiting. It is a NA study. The enrollment target is 261 participants. The study started on 2022-05-10. Estimated completion is 2028-10.

What conditions does trial NCT05124912 study?

This clinical trial studies the following conditions: Brain Metastases, Radiation Necrosis, Recurrent Tumor, Recurrent Metastases.

What interventions are being tested in trial NCT05124912?

The interventions under investigation include: Steroid Therapy (DRUG), Radiation Therapy (PROCEDURE), Laser Interstitial Thermal Therapy (PROCEDURE).

Who is sponsoring clinical trial NCT05124912?

This trial is sponsored by Monteris Medical, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05124912 being conducted?

This trial has 9 study locations across California, Illinois, Maryland, Missouri, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Brain Metastases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05124912's enrollment target sits among peer trials

261 3rd of 67 higher than 65 of 67 other Brain Metastases trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Brain Metastases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06559891 · 261 participants · NA

    THRIVE- THerapeutic IntravasculaR Ultrasound (TIVUS™) REnal Denervation System Versus Sham for the Adjunctive Treatment of Hypertension

  • NCT03713268 · 262 participants

    Intraoperative OCT Guidance of Intraocular Surgery II

  • NCT06074380 · 262 participants · Phase 4

    Non Inferiority Trial Investigating Surfactants Administered Via MIST

  • NCT06293703 · 262 participants · NA

    Effect of Limb Length Ratio on Roux-en-Y Gastric Bypass Outcomes (CLIMB II Study)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05124912, the US trial registry maintained by the National Library of Medicine. NCT05124912 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.